Advertisement
YOU ARE HERE: LAT HomeCollectionsRoche Holding Ltd
IN THE NEWS

Roche Holding Ltd

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
March 5, 2008 | From Reuters
Roche Holding and GlaxoSmithKline said Tuesday that they had added new labels to their prescription flu medicines that contain reports of abnormal psychiatric behavior in some patients. A warning about cases of delirium and unusual behavior had been listed previously on Roche's drug, Tamiflu. That language was strengthened to say some cases were fatal.
Advertisement
BUSINESS
August 29, 2007 | From Reuters
Amgen Inc. said Tuesday that a federal court had ruled that a Roche Holding product infringes an Amgen anemia drug patent. A trial on other Amgen claims that Roche infringed patents covering its anemia products is set to begin in U.S. Federal District Court in Boston on Tuesday. Thousand Oaks-based Amgen's anemia franchise, which brought in $6.6 billion in sales last year, has been under siege because of safety concerns and a pullback in coverage by the U.S.
BUSINESS
August 30, 1994 | From Times Staff and Wire Reports
Roche to Sell Syntex's Medical Diagnostic Unit: The company said it will sell the business under an agreement with the Federal Trade Commission, clearing the way for a $5.3-billion merger of the two companies. Roche Holding Ltd.'s $24-a-share tender offer for Syntex Corp. has been extended several times since being announced May 2 and will now expire Wednesday. Syntex's Syva Co. is a major provider of tests that detect illegal drugs.
BUSINESS
November 26, 2005 | From Bloomberg News
Roche Holding Ltd. said Indonesia could make a generic version of Tamiflu without its license because the medicine, which may be useful in treating avian influenza, isn't protected by a patent in the Southeast Asian nation. "We've informed the government they can produce it for local use," said Martina Rupp, a spokeswoman for the Swiss drug maker. "Quality guidelines will have to be assured by the Indonesian government."
BUSINESS
April 10, 1999 | Bloomberg News
Genentech Inc. and its majority owner, Swiss drug maker Roche Holding Ltd., said they have decided not to seek U.S. approval of a drug to promote nerve growth after trials failed to show it worked. Separately, South San Francisco, Calif.-based Genentech said it may settle with U.S. authorities in California on charges of past improper promotion of its growth hormones. If the biotechnology company and the U.S.
BUSINESS
July 8, 2006 | From Reuters
An administrative law judge has allowed drug maker Roche Holding Ltd. to continue to import an experimental anemia drug at the center of a patent fight between Roche and Amgen Inc., the companies said Friday. The judge at the U.S. International Trade Commission has determined that Roche can import its experimental drug peg-EPO, also known as Cera, under an exception for clinical trials, the companies said.
BUSINESS
November 10, 2005 | From Reuters
Amgen Inc., the world's largest biotechnology company, said Wednesday that it had sued Roche Holding Ltd., accusing the drug maker of infringing six patents covering its Epogen anemia treatment. Thousand Oaks-based Amgen said the suit, filed in U.S. District Court in Boston, sought an injunction to prevent Roche from making or selling recombinant human erythropoietin, including "pegylated" versions that last longer in the body.
NEWS
June 2, 1990 | ROBERT STEINBROOK, TIMES MEDICAL WRITER
Genentech Inc. of South San Francisco announced Friday that its scientists had successfully immunized two chimpanzees against infection with one strain of the AIDS virus. Such results, as well as similar successful tests of vaccines against AIDS-like viruses in monkeys, demonstrate that a vaccine to protect humans against the deadly disease is possible, scientists say.
BUSINESS
February 24, 2007 | From Reuters
Swiss drug maker Roche Holding said Friday that it had suspended enrollment in a clinical trial of its experimental anemia drug because of safety concerns. The news casts a further cloud over a class of drugs that include Amgen Inc.'s Aranesp and Epogen, and Johnson & Johnson's Procrit. Roche said it was temporarily suspending recruitment into a mid-stage trial of its drug, Cera, in anemic lung cancer patients because of an "imbalance" of deaths across the four arms of the study.
BUSINESS
October 21, 2006 | From Bloomberg News
Amgen Inc. can pursue a patent lawsuit that seeks to block Roche Holding from selling the anemia drug Cera in the U.S., a judge ruled Friday, agreeing to a timetable that may lead to a trial as early as May. U.S. District Judge William G. Young in Boston rejected Roche's request that the suit be thrown out because Cera isn't yet sold in the U.S. The Food and Drug Administration may decide in February whether to approve the drug, used to boost red blood cells, Amgen said.
BUSINESS
July 8, 2006 | From Reuters
An administrative law judge has allowed drug maker Roche Holding Ltd. to continue to import an experimental anemia drug at the center of a patent fight between Roche and Amgen Inc., the companies said Friday. The judge at the U.S. International Trade Commission has determined that Roche can import its experimental drug peg-EPO, also known as Cera, under an exception for clinical trials, the companies said.
BUSINESS
December 13, 2005 | From Associated Press
Swiss drug maker Roche Holding said it had chosen 12 potential partners for the production of Tamiflu and granted one sub-license for the antiviral drug to Shanghai Pharmaceutical. Basel-based Roche said it had compiled the short list of potential partners, which it did not identify, after evaluating about 200 applicants interested in helping with certain steps in the manufacturing of Tamiflu. It didn't say how many it would finally choose.
BUSINESS
November 26, 2005 | From Bloomberg News
Roche Holding Ltd. said Indonesia could make a generic version of Tamiflu without its license because the medicine, which may be useful in treating avian influenza, isn't protected by a patent in the Southeast Asian nation. "We've informed the government they can produce it for local use," said Martina Rupp, a spokeswoman for the Swiss drug maker. "Quality guidelines will have to be assured by the Indonesian government."
BUSINESS
November 10, 2005 | From Reuters
Amgen Inc., the world's largest biotechnology company, said Wednesday that it had sued Roche Holding Ltd., accusing the drug maker of infringing six patents covering its Epogen anemia treatment. Thousand Oaks-based Amgen said the suit, filed in U.S. District Court in Boston, sought an injunction to prevent Roche from making or selling recombinant human erythropoietin, including "pegylated" versions that last longer in the body.
BUSINESS
February 3, 1990 | MARTHA GROVES, TIMES STAFF WRITER
The Swiss owner of pharmaceutical giant F. Hoffmann-La Roche & Co. surprised the health-care industry Friday with an agreement to invest $2.1 billion in Genentech and obtain a 60% stake in the pioneering biotechnology firm. Industry observers embraced the deal as a savvy move for both companies that could prove to be a model for others. It provides the Swiss concern, Roche Holding Ltd., access to a large pipeline of biotech products and a sizable U.S. sales force.
BUSINESS
June 9, 1990 | MARTHA GROVES, TIMES STAFF WRITER
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
BUSINESS
August 18, 2005 | From Reuters
Genentech Inc., Swiss drug maker Roche Holding and Biogen Idec Inc. said they had completed their U.S. marketing application to expand use of their drug Rituxan to patients never before treated for non-Hodgkin's lymphoma. The popular medicine was approved in the United States in 1997 for patients with the low-grade form of that type of lymphoma who had failed to benefit from other standard therapies.
BUSINESS
May 3, 2005 | From Bloomberg News
Swiss firm Roche Holding and partners Genentech Inc. of South San Francisco and OSI Pharmaceuticals Inc. of Melville, N.Y., have asked U.S. regulators to approve the lung cancer drug Tarceva to treat pancreatic cancer. The three companies submitted an application to the Food and Drug Administration for the new use after a study showed that the drug helped patients live longer when taken with chemotherapy, Roche said.
Los Angeles Times Articles
|